Pharmacogenetic Testing for Methotrexate Treatment in Leukemia Patients

Muhammad Tahir M Bhinder, Amin Saleh Halum, Suhaib M Muflih and Mohammad Shawaqfeh**
College of Pharmacy, Nova Southeastern University, FL, USA

Abstract

Background: Pharmacogenetic testing can be used as a means to individualize a patient’s medical regimen in order to prevent future adverse drug events. Pharmacogenomics looks at individual genes and can predict a patient’s susceptibility to certain side effects of medications, as well as how efficacious a medication will be for that patient. Methotrexate has been shown to exhibit different responses based on the genetic expressions and variations of the genes SLC19A, SHMT, ABCB1, ATIC and MTHFR.

Objective: To determine the clinical relevance of pharmacogenetic testing for leukaemia patients treated with Methotrexate.

Method: A systematic review was conducted from September 2013-August 2015, primarily using the EMBASE and PubMed databases, identifying Cochrane reviews, controlled clinical trials, randomized control trials, meta-analyses and systematic reviews. Search terms that were initially included were the name of the genes individually (SLC19A, SHMT, ABCB1, ATIC and MTHFR), methotrexate, and leukemia. The results were further limited to English and those conducted on humans. Two reviewers extracted data and evaluated pertinent studies. A total of 82 articles were found, but were then narrowed down to 34 articles. The 34 articles were graded with the JADAD scale, with scores ranging from 0-5 points. They were then evaluated for clinical relevance, and were reduced to 10 articles to be analysed for the purpose of the study.

Results: Of the 34 article graded, 26 articles had a score of 0 points.

Conclusion: Although there is significant evidence of an association between the clinical effects of methotrexate in leukemia patients and these genes, based on their JADAD scores, there appears to be a lack of high evidence clinical studies. None of the article found included randomized controlled trials, despite compelling evidence indicating a need for these high quality studies in order to administer methotrexate to patients in a safer manner.

Keywords: Methotrexate; Pharmacogenetic testing; Leukemia

Introduction

The ideal target of pharmacotherapy is to have optimal clinical outcomes, characterized by the complete treatment of a health illness with minimal adverse effects. As of today, is this possible? Until recently, health care providers had no idea why certain patients have a positive response to a drug therapy while others experience side effects from same therapy. It is known that patients can achieve better results when receiving individualized treatment, possibly because individualized medicine requires that one seeks a deep understanding on how medicine is metabolized by an individual’s body. Although clinical practice experience indicates that to be mostly true, how can we assure the best health care of tomorrow?

A form of providing individualized care is called pharmacogenomics or pharmacogenetics. As described by the FDA, “pharmacogenomics allows one to identify sources of an individual’s profile of drug response and predict the best possible treatment option for this individual. The use of genomic information has opened new possibilities in drug discovery and development.” The FDA provides a table of pharmacogenomics biomarkers in drug label, in order to identify responders and non-responders to medications, avoid adverse events, and optimize drug dose. Drug label may contain information on genomic biomarkers and can describe: drug exposure and clinical response variability, risk for adverse events, genotype specific dosing, mechanisms of drug action, and polymorphic drug target and disposition genes. For example, due to the fact that medications like codeine do not properly work for some individuals, specifically those considered ultra-rapid metabolizers for CYP2D6; the FDA has issued boxed warnings with use for this specific population, including counseling information [1].

There are many studies proposing that, by selecting treatment based on a patient’s specific genes via pharmacogenetic testing, we can predict the probability of success or failure of a particular pharmacotherapy. Based on individual specific genetic differences, pharmacogenetics can explain existing variability in drug response from its metabolism to adverse reactions. Methotrexate is commonly used as a chemotherapeutic agent for childhood acute lymphoblastic leukemia (ALL), amongst other diseases. However, treatment is limited due to severe toxicity or low efficacy of treatment for certain patients. Methotrexate has been shown to exhibit different responses based on the genetic expressions and variations of the genes SLC19A, SHMT, ABCB1, ATIC and MTHFR. For this literature evaluation, we examined the clinical relevance of pharmacogenetics testing for leukemia patients treated with Methotrexate. Furthermore, the treatment outcome for
patients with each of these genes will be taken into account as we evaluate the relevance of pharmacogenomics testing to predict these responses.

**Method**

In order to determine the extent to which pharmacogenetic testing could impact the clinical outcomes of leukemia patients treated with methotrexate, a literature search needed to be done. This would allow one to better understand the relationship between methotrexate toxicity and the genetic make-up of leukemia patients, in regards to the five specific genes. A systematic review (Figure 1) was conducted from September 2013-August 2015, primarily using the EMBASE and PubMed databases, identifying Cochrane reviews, controlled clinical trials, randomized control trials, meta-analyses and systematic reviews. Initially, the search terms included the name of each gene individually (SLC19A, SHMT, ABCB1, ATIC and MTHFR), methotrexate and leukemia. Two reviewers extracted data and evaluated pertinent studies. A total of 82 relevant articles were found, which were then further limited to English and those conducted on humans. The remaining articles were narrowed down, based on relevance to the study objective, leaving a total of 34 articles. The articles of interest were then graded using the JADAD grading scale to determine the strength of each article. The JADAD grading scale, which is sometimes known as JADAD scoring, is used as a grading method to define the quality of a clinical trial. Studies are individually evaluated and given a score between zeros (very poor) to five (rigorous). Since randomized control trials are considered of great importance for medical science advancement, those studies are given the highest scores. This grading criterion takes into consideration methodological errors such as selection bias and/or lack of blind-randomization, thus deducting points from those studies. Additional points are given to studies if an appropriate method of randomization or blinding was described in the paper. Sample questions for JADAD are as follows: Was the study described as randomized? Was the study described as double blind? Was there a description of withdrawals and drop-outs?

The JADAD grading scale assigns numerical points to each article based on whether it is a randomized controlled trial, if the sequence of randomization was described, if the study was double blind, a description double-blinding technique, and if there were drop-outs in the study. Based on the JADAD scores, a total of 10 articles where primarily chosen for the purpose of the study.

**Results**

The initial literature search, mainly using the EMBASE and PubMed databases, gave us 82 potential articles to determine the clinical relevance of pharmacogenomics testing in leukemia patients. As mentioned in the methods section, only 34 articles were used to evaluate and score using the JADAD scale. Determining the articles emphasis on the search terms also narrowed these 34 articles down. Our evaluation resulted in 26 articles with a score of zero, 5 articles with 1 point, 2 articles with 2 points and 1 article that scored 3 points. A total of 10 articles were then chosen based on the content (Table 1).

**Discussion**

Drug monitoring is crucial due to high variability in the pharmacokinetics of methotrexate. Methotrexate with folinic acid rescue is widely used as chemotherapy in children with acute lymphoblastic leukemia (ALL) and malignant lymphoma (ML). The different genetic expression of an individual accounts for the variability in response to treatment with methotrexate.
occurred in the consolidation phase in the ALL therapy of the Lebanese children [3]. Although theoretically ABCB1 gene polymorphism would be expected to decrease methotrexate clearance, lack of randomized controlled trials prevents us from formulating a certain conclusion.

MTHFR

5, 10-methylenetetrahydrofolate reductase, (MTHFR), is an important enzyme in the folate/methotrexate metabolism pathway. It catalyzes the conversion of 5, 10-methylenetetrahydrofolate to 5-methyltetrahydrofolate in the folic acid cycle. Frequency of 677T, A1298C and G80A allelic variants differ in individuals and ethnicities. Differences in MTHFR activity due to these genetic variants might modify the therapeutic response to anti folate chemotherapeutic agents, including methotrexate [4].

Based on a study conducted in Hospital Oswald Cruz in Brazil, paediatric patients with 677TT genotype had a better overall survival rate than the patients with 677CC genotype for the MTHFR gene. There was a better overall survival rate for the 1298CC genotype, and although the 80AA genotype had the lowest MTX plasma level up to 24 hours, it showed a small reduction of MTX plasma concentrations in the period of 24 to 48 hours. Thus, we can suggest that patients carrying the 80AA genotype have difficulty in the metabolism of the chemotherapeutic agents to transport the drug into the cell, and thus, exhibit adverse effects [4]. In another study at the Paediatric Department of the Second University of Naples, the roles of the C677T and A1298C genes are compared. Two common polymorphisms, a 677C to T transition and a 1298A to C transition, lead to 30–60% reduction in enzyme activity in the MTHFR gene. Therefore, patients with decreased MTHFR activity are at an increased risk of MTX-related toxicity. The analysis shows that patients with 677TT genotype had a 13 fold increased risk of developing non-haematological toxicity in the 2 gram MTX dose subgroup when compared to other genotypes and doses [5].

These results contraindicate the previous study mentioned where the MTHFR C677T allele does not increase the risk of MTX induced toxicities in ALL children. This goes to show that more research needs to be done because the same alleles in a gene, such as MTHFR, show different results; one showing higher survival rate, and in another study showing a 13 fold increase risk in MTX toxicities. It could be due not only to pharmacogenetics, but also the different dosages given.

AT1C

Methotrexate enters cells through a reduced folate carrier and is activated by polyglutamation to MTX polyglutamate. The sequential addiction of residues enhances the intracellular retention of MTX and promotes the inhibition of 5-aminomimidazole -4- carboxamide ribonucleotide transformylase (AICAR) transformylase (AT1C). This is the last enzyme in the purine synthesis pathway. This could lead to the accumulation of adenosine deaminase. Genetic polymorphism in the AT1C gene, among other genes, may account for part of the variability among patients in the therapeutic response to MTX [6,7]. A cross sectional study conducted at a community based Rheumatology clinic in Knoxville, TN concluded that there is a poor association between the dosage of methotrexate and its effects, but did find that patients with the AT1C C347G polymorphism did experience fewer side effects compared to patients with the AT1C 347CC or AT1C 347CG genotypes [6].

SLC19, SHMT

The reduced folate carrier SLC19 is involved with the cellular uptake of MTX. SHMT plays a role in one carbon pathway, including the conversion of tetrahydrofolate to 5, 10- methylenetetrahydrofolate [8,9]. Different studies have been done to determine how polymorphism in these genes affects methotrexate treatment. Most studies have been inconclusive specific to these genes [10].

Overall, lack of high quality studies makes it difficult to assess the impact of polymorphism in these genes in leukemia patients taking methotrexate. The majority of the articles chosen received a score of zero on the JADAD scale, indicating a need for higher quality studies in order to be able to make a conclusion on the how pharmacogenetic testing may be able to decrease side effects and toxicity of methotrexate in leukemia patients.

Limitations

Some of the limitations that were encountered during the study were that no randomized controlled studies were found, which a gold standard trial for research studies is. Most of the articles used were on studies that had associations between the different genes, methotrexate and leukemia.

Also, two articles found results that were contraindicating to each other regarding the MTHFR gene. In one of the articles, “Methotrexate toxicity and efficacy during the consolidation phase in pediatric acute lymphoblastic leukemia and MTHFR polymorphisms as pharmacogenetic determinants”, the C677T allele in the MTHFR gene had a 13- fold increase risk of developing MTX toxicity. On the
other hand, in the article, “Influence of Methylenetetrahydrofolate Reductase C677T, A1298C, and G80A Polymorphisms on the Survival of Pediatric Patients with Acute Lymphoblastic Leukemia”, the C677T allele showed it had a higher survival rate. This goes to show that more research needs to be done in patients with different genotypes as well as patients receiving different dosing of MTX. It was very difficult to find quality, evidence based research articles on the relationship between the genotypes and MTX dosing, and the side effects in leukemia patients. Another limitation that was encountered is that there were more studies on rheumatoid arthritis patients rather than leukemia patients. This was the main population that we wanted to study regarding methotrexate treatment and the responses of the different genotypes. Also, the few articles that were found about leukemia were those conducted outside of the United States in different countries such as Lebanon and China.

Conclusion

Based on this literature review, we analysed the results from our grading table and concluded that we currently lack strong evidence to support any specific pharmacogenetic testing to predict the response of methotrexate treatment in patients with childhood ALL. The main reason for this fact is that the trials were not designed to meet our current gold standard criteria of double blind randomized control trials. Because methotrexate is considered an invasive therapy with high potential for side effects and adverse reactions, it is ideal to be able to pre-test a patient to see if this therapy will potentially work or not. At this moment, it was found that there is a need of stronger evidence in order to affirm any specific pharmacogenetic testing to predict the response of methotrexate. Based on this finding, we recommend that double blind randomized control trials are designed to support stronger evidence of the effectiveness of a specific pharmacogenetic test prior to methotrexate treatment. By following this approach, we can possibly be able to provide a more individualized treatment for patients with childhood acute lymphoblastic leukemia (ALL). This will help diminish side effects, adverse reactions, and any potential health risk to the patient, making methotrexate therapy safer and more effective.

References

1. Table of Pharmacogenomic Biomarkers in Drug Labeling (2014).